BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6119712)

  • 1. Initial improvement as predictor of outcome of neuroleptic treatment.
    Nedopil N; Rüther E
    Pharmacopsychiatria; 1981 Nov; 14(6):205-7. PubMed ID: 6119712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients.
    Nedopil N; Pflieger R; Rüther E
    Pharmacopsychiatria; 1983 Nov; 16(6):201-5. PubMed ID: 6141576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients].
    Möller HJ; Scharl W; von Zerssen D
    Fortschr Neurol Psychiatr; 1985 Oct; 53(10):370-83. PubMed ID: 2866152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modification of long-term schizophrenia by somato-therapeutic measures].
    Gross G; Huber G; Schüttler R
    Psychiatr Clin (Basel); 1980; 13(3-4):179-92. PubMed ID: 6113621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in the health state of schizophrenic patients in neuroleptic therapy].
    Heim M
    Psychiatr Neurol Med Psychol (Leipz); 1986 Aug; 38(8):483-7. PubMed ID: 2878452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroleptic treatment and neurological soft signs in schizophrenic patients].
    Mechri A; Slama H; Chebel S; Mandhouj O; Gaha L
    Therapie; 2007; 62(5):449-53. PubMed ID: 18206107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study].
    Schmidt LG; Siemetzki H
    Nervenarzt; 1988 Dec; 59(12):721-6. PubMed ID: 2905770
    [No Abstract]   [Full Text] [Related]  

  • 9. [Neuroleptic large dose therapy of schizophrenias].
    Ungvári G; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Apr; 33(4):230-6. PubMed ID: 6114506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
    Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
    Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment? Results of a preliminary study.
    Meya U; Renfordt E
    Pharmacopsychiatry; 1986 Nov; 19(6):429-33. PubMed ID: 2879296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suspension of neuroleptic therapy in acute schizophrenia.
    Kuhs H; Eikelmann B
    Pharmacopsychiatry; 1988 Jul; 21(4):197-202. PubMed ID: 2905064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement.
    Bartkó G; Herczeg I; Békésy M
    J Clin Psychiatry; 1987 Sep; 48(9):363-5. PubMed ID: 3624207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Psychopathometric study of the prognostic significance of psychopathologic findings and premorbid personality for discharge of neuroleptic treated patients with schizophrenic psychoses].
    Möller HJ; von Zerssen D
    Nervenarzt; 1985 Sep; 56(9):498-505. PubMed ID: 2867479
    [No Abstract]   [Full Text] [Related]  

  • 16. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
    Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
    Greenberg JS; Brown WA; Laughren TP; Krantz J
    Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.